New Grading System and Treatment Guidelines for the Acute Ocular Manifestations of Stevens-Johnson Syndrome.
To describe a new grading system and associated treatment guidelines for the acute ocular manifestations of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).



Prospective case series.



Seventy-nine consecutive patients (158 eyes) evaluated and treated for acute ocular involvement in SJS or TEN during hospitalization.



Photographic and chart review of acute ocular findings, interventions received, and outcomes with regard to visual acuity, dry eye symptoms, and scarring sequelae at least 3 months after the acute illness.



Visual acuity, dry eye severity, and scarring of the ocular surface and eyelids were assessed after follow-up of at least 3 months.



Cases graded as mild or moderate were managed medically. All had best-corrected visual acuity (BCVA) of 20/20, no dry eye symptoms, and no scarring sequelae. Cases graded as severe or extremely severe were treated with urgent amniotic membrane transplantation (AMT) in addition to medical management. Severe cases all had BCVA of 20/20 and mild or no dry eye problems. Five of 28 patients had mild tarsal conjunctival scarring. No other scarring sequelae occurred. Nine of the 10 extremely severe cases had BCVA of 20/20 (1 was 20/30). Three of 10 had moderate scarring of the tarsal conjunctiva and lid margins and also moderate dry eyes with severe photophobia. Seven of 10 had only mild or no dry eye symptoms and scarring sequelae.



This grading system facilitates decision making in the evaluation and management of the acute ocular manifestations of SJS and TEN. Mild and moderate cases have a low risk of significant scarring or visual sequelae and may be monitored and treated medically if not worsening. Severe and extremely severe cases should receive urgent AMT to decrease the risk of scarring and visual sequelae.
Department of Ophthalmology, University of Colorado School of Medicine, Aurora, Colorado. Electronic address: darren.gregory@ucdenver.edu.
Darren G
DG
Gregory
D000208:Acute Disease; D000650:Amnion / Q000637:transplantation*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D016572:Cyclosporine / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D015352:Dry Eye Syndromes / Q000175:diagnosis; D005141:Eyelid Diseases / Q000175:diagnosis; D005260:Female; D015590:Fluorophotometry; D024841:Fluoroquinolones / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use*; D017408:Guidelines as Topic; D006801:Humans; D008875:Middle Aged; D000077266:Moxifloxacin; D011446:Prospective Studies; D012720:Severity of Illness Index; D013262:Stevens-Johnson Syndrome / Q000145:classification / Q000175:diagnosis* / Q000628:therapy*; D014031:Tobramycin / Q000627:therapeutic use; D014792:Visual Acuity / Q000502:physiology
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D005938:Glucocorticoids; D003907:Dexamethasone; D016572:Cyclosporine; D000077266:Moxifloxacin; D014031:Tobramycin